SNY

The drugmaker said efficacy and safety data didn't support further development of the drug, amlitelimab, for atopic dermatitis.

Sanofi today announced discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis.

Sanofi evolves its Executive Committee to support its next strategic chapter Paris, July 21, 2026. Sanofi today announced an evolution of its Executive Committee, bringing together a focused leadership team across its businesses, scientific organization and key global functions as the company continues to deliver on its priorities and prepares its next strategic chapter.

PARIS & LONDON--(BUSINESS WIRE)-- #DrugDiscovery--Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and.

Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

The U.S. Food ​and Drug ‌Administration said on Friday ​it has ​approved Sanofi's blood ⁠cancer drug, ​Sarclisa, which ​can be given under the ​skin through ​a wearable injector, ‌offering ⁠multiple myeloma patients a less burdensome ​alternative ​to ⁠intravenous infusions.

The European Commission said on Wednesday ​it would seek feedback ‌on commitments offered by French pharmaceutical company Sanofi to ​address concerns that ​it may have breached competition ⁠rules in a ​flu vaccine marketing campaign.

Sanofi's phase III Baby-COMET study meets all goals for Nexviazyme in infantile-onset Pompe disease, paving the way for a planned U.S. filing in H2 2026.

Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results.

The European Commission opened on Friday an ​investigation into whether French ‌drug giant Sanofi breached EU competition rules in a flu ​vaccine marketing campaign.